US FDA approves Ionis therapy Zanvastro for rare brain disorder
The U.S. FDA approved Ionis Pharmaceuticals’ zilganersen (Zanvastro) to treat a rare genetic disorder affecting the brain’s white matter, with use for adults and pediatric patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.